Lucas Calduch Ana, Arnaiz Fernández María Dolores, San José Maderuelo Sol, Navarro Pérez Valentí, Serrano Bermúdez Gala, Montes Borinaga Ana, Cardenal Alemany Felipe, Jeremic Branislav, Guedea Edo Ferran
Servicio de Oncología Radioterápica, Institut Català d'Oncologia, Barcelona, España.
Clin Transl Oncol. 2005 Aug;7(7):314-20. doi: 10.1007/BF02710271.
We retrospectively reviewed our Institution's database to investigate the outcome and impact of combined radiochemotherapy (RT/CT; concomitant or in sequence) in localised small-cell lung cancer (L-SCLC).
Between January 1995 to November 1999, 79 patients with L-SCLC received combined RT/CT at our Institution. RT was delivered concurrently or sequentially following the CT. Patients with treatment response received additional prophylactic cranial irradiation (PCI).
Of the patients treated, 54% had received concurrent CT/RT compared to 46% receiving RT following the CT. PCI was administered to 80% of the patients. Complete response was observed in 66% of patients. With a median follow up of 30 months, median overall survival was 15.9 months; 14.3 months for patients who received RT following CT and 21.6 months for those receiving concurrent CT/RT. The type of schedule of combined radiochemotherapy was an independent prognostic factor for survival free of local recurrence, as was additional PCI for distant metastasis-free survival.
Our results are similar to those reported previously in the literature. The main point of interest is that our patients were non-selected. We strongly support the use of concurrent CT/RT so as to achieve results comparable to the best in the literature.
我们回顾性分析了本机构的数据库,以研究局部小细胞肺癌(L-SCLC)同步或序贯放化疗(RT/CT)的疗效及影响。
1995年1月至1999年11月期间,79例L-SCLC患者在本机构接受了同步或序贯放化疗。放疗在化疗后同步或序贯进行。治疗有效的患者接受了额外的预防性颅脑照射(PCI)。
接受治疗的患者中,54%接受了同步放化疗,46%接受了化疗后放疗。80%的患者接受了PCI。66%的患者观察到完全缓解。中位随访30个月,中位总生存期为15.9个月;化疗后放疗的患者为14.3个月,同步放化疗的患者为21.6个月。放化疗联合方案的类型是无局部复发生存期的独立预后因素,额外的PCI是无远处转移生存期的独立预后因素。
我们的结果与先前文献报道的结果相似。主要关注点在于我们的患者未经过筛选。我们强烈支持使用同步放化疗,以取得与文献中最佳结果相当的疗效。